MarketCap
Facebook
X
TelegramQuarterly report 2023-Q2
added 08-14-2023
Biocept Retained Earnings 2011-2026 | BIOC
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings Biocept
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -298 M | -266 M | - | -246 M | -220 M | -195 M | -174 M | -155 M | -138 M | -122 M | -113 M | -101 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -101 M | -298 M | -185 M |
Quarterly Retained Earnings Biocept
| 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -309 M | -306 M | -298 M | -280 M | -274 M | -269 M | -266 M | -263 M | -263 M | -261 M | -264 M | -264 M | -264 M | -264 M | -246 M | -246 M | -246 M | -246 M | -220 M | -220 M | -220 M | -220 M | -195 M | -195 M | -195 M | -195 M | -174 M | -174 M | -174 M | -174 M | -155 M | -155 M | -155 M | -155 M | -138 M | -138 M | -138 M | -138 M | -122 M | -122 M | -122 M | -122 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -122 M | -309 M | -211 M |
Retained Earnings of other stocks in the Diagnostics research industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
-62.9 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Agilent Technologies
A
|
348 M | $ 114.84 | -0.55 % | $ 34.9 B |  USA |
 |
Oxford Immunotec Global PLC
OXFD
|
-84 M | - | - | $ 562 M |  Britain |
|
Akumin
AKU
|
-280 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Burning Rock Biotech Limited
BNR
|
-2.23 B | $ 16.3 | 0.62 % | $ 175 M |  China |
 |
Aspira Women's Health
AWH
|
-544 M | - | -6.19 % | $ 10.5 M | USA |
 |
Accelerate Diagnostics
AXDX
|
-607 M | - | -61.36 % | $ 2.46 M | USA |
 |
Global Cord Blood Corporation
CO
|
2.89 B | - | - | $ 399 M | China |
 |
Fluidigm Corporation
FLDM
|
-624 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
-150 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
-4.94 B | - | 0.12 % | $ 80.1 M | China |
 |
PRA Health Sciences, Inc.
PRAH
|
440 M | - | - | $ 10.7 B | USA |
|
Biodesix
BDSX
|
-462 M | $ 15.36 | 1.92 % | $ 1.99 B | USA |
 |
QIAGEN N.V.
QGEN
|
2.75 B | - | - | $ 10.6 B |  Niderland |
 |
CareDx, Inc
CDNA
|
-735 M | $ 17.82 | -2.68 % | $ 950 M | USA |
 |
Anixa Biosciences
ANIX
|
-252 M | $ 2.59 | 1.57 % | $ 84.1 K | USA |
 |
Biomerica
BMRA
|
-53.2 M | $ 2.17 | - | $ 4.98 M | USA |
 |
BioNano Genomics
BNGO
|
-720 M | $ 1.15 | -4.17 % | $ 6.26 M | USA |
 |
Check-Cap Ltd.
CHEK
|
-170 M | - | - | $ 9.42 M |  Israel |
 |
Co-Diagnostics
CODX
|
-80.4 M | $ 4.4 | 101.83 % | $ 5.85 M | USA |
 |
Charles River Laboratories International
CRL
|
1.39 B | $ 168.22 | -3.26 % | $ 8.34 B | USA |
 |
Castle Biosciences
CSTL
|
-200 M | $ 24.73 | -0.44 % | $ 687 M | USA |
 |
Celcuity
CELC
|
-449 M | $ 114.22 | 1.41 % | $ 5.34 B | USA |
 |
Danaher Corporation
DHR
|
46.9 B | $ 192.12 | 0.53 % | $ 137 B | USA |
 |
DermTech
DMTK
|
-424 M | - | -11.32 % | $ 2.94 M | USA |
 |
DexCom
DXCM
|
2.43 B | $ 63.21 | 1.59 % | $ 24.7 B | USA |
 |
Chembio Diagnostics
CEMI
|
-154 M | - | 0.22 % | $ 16.8 M | USA |
 |
Enzo Biochem
ENZ
|
-294 M | - | -8.98 % | $ 14.8 K | USA |
 |
Exact Sciences Corporation
EXAS
|
-4.71 B | - | - | $ 19.8 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
9.99 B | $ 198.96 | 0.91 % | $ 22.1 B | USA |
 |
Fulgent Genetics
FLGT
|
590 M | $ 16.42 | -2.38 % | $ 496 M | USA |
 |
Guardant Health
GH
|
-2.99 B | $ 89.66 | -4.44 % | $ 11.2 B | USA |
 |
Heska Corporation
HSKA
|
-169 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-230 M | - | -20.0 % | $ 1.06 M | USA |
 |
ICON Public Limited Company
ICLR
|
2.72 B | $ 109.62 | -4.0 % | $ 9.04 B |  Irlanda |
 |
Interpace Biosciences
IDXG
|
-211 M | $ 1.97 | 0.63 % | $ 8.72 M | USA |
 |
Illumina
ILMN
|
-1.24 B | $ 127.74 | 0.28 % | $ 20.3 B | USA |
 |
IQVIA Holdings
IQV
|
7.42 B | $ 170.72 | -1.47 % | $ 29.3 B | USA |
 |
Laboratory Corporation of America Holdings
LH
|
8.64 B | $ 274.46 | 0.27 % | $ 22.8 B | USA |
 |
Lantheus Holdings
LNTH
|
680 M | $ 75.89 | -0.28 % | $ 5.12 B | USA |
 |
Medpace Holdings
MEDP
|
-460 M | $ 496.0 | -0.47 % | $ 14.3 B | USA |
 |
Motus GI Holdings
MOTS
|
-154 M | - | -34.28 % | $ 263 K | Israel |
 |
Mettler-Toledo International
MTD
|
9.24 B | $ 1 266.63 | 0.53 % | $ 26.1 B |  Schweiz |
 |
Myriad Genetics
MYGN
|
-1.12 B | $ 4.67 | -1.68 % | $ 432 M | USA |
 |
ENDRA Life Sciences
NDRA
|
-110 M | $ 4.74 | 1.07 % | $ 3.73 M | USA |
 |
NeoGenomics
NEO
|
-434 M | $ 8.02 | 0.25 % | $ 1.03 B | USA |
 |
Neogen Corporation
NEOG
|
-536 M | $ 9.56 | 1.59 % | $ 2.07 B | USA |
 |
National Research Corporation
NRC
|
-17.3 M | $ 17.33 | 0.99 % | $ 388 M | USA |